Ana Rita Cruz-Machado

Association Between Tumor Necrosis Factor Inhibitors and the Risk of Hospitalization or Death Among Patients With Immune-Mediated Inflammatory Disease and COVID-19

Zara Izadi, Erica J. Brenner, Satveer K. Mahil et al. · JAMA Network Open · 2021 · 114 citations · Full text

Increased monohexosylceramide levels in the serum of established rheumatoid arthritis patients

Gábriel Miltenberger-Miltényi, Ana Rita Cruz-Machado, Jennifer T. Saville et al. · Lara D. Veeken · 2019 · 27 citations · Full text

Real-world Longterm Effectiveness of Tumor Necrosis Factor Inhibitors in Psoriatic Arthritis Patients from the Rheumatic Diseases Portuguese Register

Elsa Vieira‐Sousa, Mónica Eusébio, Pedro Ávila-Ribeiro et al. · The Journal of Rheumatology · 2019 · 24 citations

Eligibility criteria for biologic disease-modifying antirheumatic drugs in axial spondyloarthritis: going beyond BASDAI

José Marona, Alexandre Sepriano, Santiago Rodrigues-Manica et al. · RMD Open · 2020 · 19 citations · Full text

A COVID-19 outbreak in a rheumatology department upon the early days of the pandemic

Vasco C. Romão, Filipa Oliveira‐Ramos, Ana Rita Cruz-Machado et al. · 2020 · 14 citations · Full text

Virus Epidemiology, Viral Diagnostics, Covid-19 Outbreak +18